NasdaqGS - Delayed Quote USD

Atea Pharmaceuticals, Inc. (AVIR)

3.7100

+0.0200

(+0.54%)

At close: April 26 at 4:00 PM EDT

3.7100

0.00

(0.00%)

After hours: April 26 at 4:20 PM EDT

Key Events

Loading Chart for AVIR

9/21 12:03 PM

DELL

Previous Close 3.6900
Open 3.7100
Bid 3.6900 x 300
Ask 3.7500 x 100
Day's Range 3.6523 - 3.7200
52 Week Range 2.7650 - 5.1900
Volume 137,512
Avg. Volume 390,750
Market Cap (intraday) 312.25M
Beta (5Y Monthly) 0.16
PE Ratio (TTM) --
EPS (TTM) -1.6300
Earnings Date May 6, 2024 - May 10, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 3.50

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

75

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AVIR

21.64%

S&P 500

6.92%

1-Year Return

AVIR

12.77%

S&P 500

25.26%

3-Year Return

AVIR

89.81%

S&P 500

22.00%

5-Year Return

AVIR

--

S&P 500

55.96%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Atea Pharmaceuticals, Inc.

3.7100

+0.54%

Mkt Cap 312.25M

Industry Biotechnology

Instil Bio, Inc.

10.60

+2.02%

Mkt Cap 68.941M

Industry Biotechnology

Reneo Pharmaceuticals, Inc.

1.6700

+1.21%

Mkt Cap 55.813M

Industry Biotechnology

1.3500

+4.65%

Mkt Cap 37.669M

Industry Biotechnology

Spero Therapeutics, Inc.

1.4600

+2.10%

Mkt Cap 78.684M

Industry Biotechnology

CytomX Therapeutics, Inc.

1.5900

-0.62%

Mkt Cap 107.694M

Industry Biotechnology

Spruce Biosciences, Inc.

0.7000

-0.14%

Mkt Cap 28.807M

Industry Biotechnology

26.68

+0.45%

Mkt Cap EUR 1.758B

Industry Biotechnology

Tharimmune, Inc.

0.3691

+2.50%

Mkt Cap 4.352M

Industry Biotechnology

Assembly Biosciences, Inc.

12.65

-5.31%

Mkt Cap 69.357M

Industry Biotechnology

Precision BioSciences, Inc.

9.38

-3.50%

Mkt Cap 64.874M

Industry Biotechnology

Valuation Measures

As of 4/27/2024

Market Cap

312.25M
Enterprise Value

-263.45M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

0.56
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

1.61

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-11.89%
Return on Equity (ttm)

-22.74%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-135.96M
Diluted EPS (ttm)

-1.6300

Balance Sheet and Cash Flow

Total Cash (mrq)

578.11M
Total Debt/Equity (mrq)

0.43%
Levered Free Cash Flow (ttm)

-9.44M

AVIR does not have Company Insights

ATHA Athira Pharma, Inc.

1.9200

0.00%

KOD Kodiak Sciences Inc.

3.2800

+2.98%

PRLD Prelude Therapeutics Incorporated

4.0700

+0.74%

ALLK Allakos Inc.

1.0200

+0.99%

ITOS iTeos Therapeutics, Inc.

10.80

+1.89%

ALLO Allogene Therapeutics, Inc.

2.8900

+1.23%

SEER Seer, Inc.

1.9100

+9.14%

CCCC C4 Therapeutics, Inc.

6.17

-1.12%

ALXO ALX Oncology Holdings Inc.

16.86

-0.06%

FHTX Foghorn Therapeutics Inc.

5.49

+4.97%

KYMR Kymera Therapeutics, Inc.

33.37

+0.06%

MRVI Maravai LifeSciences Holdings, Inc.

7.70

+1.58%

OM Outset Medical, Inc.

2.4000

+0.84%

ALEC Alector, Inc.

5.25

+9.15%

BBIO BridgeBio Pharma, Inc.

24.88

+2.26%

BCAB BioAtla, Inc.

2.5400

+12.89%